Darren Smyth’s latest IPKat post concerns the recent decision on a preliminary point in Resolution Chemicals Ltd v H. Lundbeck A/S, and Lundbeck’s SPC for escitalopram.
The case was an action for revocation of Lundbeck’s SPC for invalidity of the underlying patent, and the judgement mainly concerned whether Resolution was estopped from bringing the action by privity of interest with the claimants in an earlier case relating to the same SPC.